Gentian Diagnostics ASA Overview
Pro stress-test →Gentian Diagnostics develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The company utilizes PETIA (particle-enhanced turbidimetric immunoassays), based on proprietary nanoparticle technology, to convert existing biomarkers to the most efficient automated, high-throughput analysers.
Strategic Profile
Pro stress-test →Gentian's portfolio and pipeline of diagnostic reagents span areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine. The company's PETIA technology enables 3-10x higher throughput than traditional immunoassay platforms, significantly improving laboratory productivity and cost-efficiency. Full year 2025 sales of NOK 176.5 million were up 16% (17% organic growth) vs 2024.
Competitive Landscape
Pro stress-test →Gentian operates in the clinical diagnostics market serving OEM partners, distributors, and healthcare providers globally. The company competes with established IVD manufacturers and diagnostics companies offering immunoassays on clinical chemistry platforms. Gentian's differentiation lies in its proprietary PETIA nanoparticle technology enabling higher throughput and efficiency compared to traditional platforms.
Industry Context
Gentian Diagnostics ASA operates in In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics.
Key facts
Founded: 2001 · Headquarters: Moss, Norway · Revenue: NOK 176.5M (2025)